Real-World Effectiveness of Primary Series and Booster Doses of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2 Variant Infection in China: A Retrospective Cohort Study

BACKGROUND: China has been using inactivated coronavirus disease 2019 (COVID-19) vaccines as primary series and booster doses to protect the population from severe to fatal COVID-19. We evaluated primary and booster vaccine effectiveness (VE) against Omicron BA.2 infection outcomes. METHODS: This wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Lin, Wang, Fu-Zhen, Rodewald, Lance E, Wang, Xuan-Yi, Liu, Si-Yu, Liu, Qian-Qian, Wang, Xiao-Qi, Wu, Dan, Li, Ming-Shuang, Zhang, Qian, Shao, Yi-Ming, Huang, Li-Fang, Song, Yu-Dan, Huang, Yong, Zeng, Xiang, Liu, Li-Jun, Yang, Hong, Huang, Ao-Di, Bao, Li-Ming, Zheng, Hui, Ma, Chao, Lv, Xiao-Ya, Song, Lei, Ma, Zhao, Wang, Shu-Guang, Ma, Hao, Guan, Wei-Jie, Wu, Zhi-Yin, Zhong, Nan-Shan, Yin, Zun-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420401/
https://www.ncbi.nlm.nih.gov/pubmed/37005365
http://dx.doi.org/10.1093/infdis/jiad090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420401/
https://www.ncbi.nlm.nih.gov/pubmed/37005365
http://dx.doi.org/10.1093/infdis/jiad090

Ejemplares similares